Researchers published an economic evaluation in the British Journal of Cancer assessing whether adding AI to the UK breast screening pathway is cost-effective. The analysis compared AI-driven diagnostic tooling alongside standard mammography under a cost-benefit framework. The report informs payers and health systems evaluating whether AI integration can improve outcomes without disproportionate cost increases. It also provides a concrete basis for procurement and deployment planning within breast cancer screening operations. For developers, the study underscores the growing linkage between clinical performance and implementation economics as AI tools move toward broader adoption.